Unilever 1Q26 Beat Reveals Homecare’s Structural Reacceleration and Latam Turnaround Potential

Core Thesis

Unilever’s 1Q26 underlying sales growth of +3.8% (300bps of volume, 90bps of price) exceeded consensus of +3.6% by 20bps, with the beat concentrated entirely in Homecare (+6.1% vs consensus +3.9%). The result demonstrates that corrective actions in Brazil (deodorants and laundry) and improving competitiveness in India are driving a volume-led reacceleration in the company’s two largest emerging markets, offsetting persistent softness in European developed markets. FY26 guidance is reaffirmed (USG at low end of 4-6% range, volume >2%, modest margin expansion), but the composition of the beat—volume-heavy, price-light—raises questions about pricing power persistence. The key investment debate is whether Homecare’s momentum can be sustained into H2 when commodity cost tailwinds to pricing fade, and whether the Beauty & Wellbeing slowdown is cyclical or structural.

What the Market May Be Underpricing

The consensus view has been that Unilever’s growth acceleration in H2 2025 was a one-off driven by easy comps and price carryover. The 1Q26 data challenges that: volume growth accelerated to +2.9% (vs consensus +1.8%), the highest since 1Q24, and Homecare volumes surged +6.2%. The sequential improvement in Latam USG—from +3.2% in 4Q25 to +6.2% in 1Q26—is the strongest evidence that the Brazil reset (format mix improvements in laundry and deodorants) is gaining traction rather than fading. India also accelerated to +7% USG (4Q25: +5%), with volumes up +6%. These are not easy comp quarters; they reflect genuine competitive share recapture in the two markets that collectively represent ~25% of group revenue.

The €750m of cost savings already delivered against an €800m target (2024-26) implies ~€80m of the €130m FY26 goal was achieved in Q1 alone. This front-loaded execution reduces execution risk on margin guidance and provides a buffer against any H2 volume deceleration. Consensus FY26 underlying operating margin of 20.1% may prove conservative if volume momentum persists and pricing recovers in Homecare as commodity costs rise.

Evidence Chain

Homecare is the structural surprise. The division’s +6.1% USG was 218bps above division-level consensus, driven entirely by volume (+6.2%) with price slightly negative (-0.1%). India fabric cleaning liquids grew +DD% and strengthened market leadership; Brazil returned to positive volumes after H2 2025 corrective actions on price gaps. Premium liquids were +DD% globally. The volume-heavy nature of this growth is more sustainable than price-led growth because it reflects improved competitiveness rather than pricing power extraction. However, the price mix is negative, meaning the division is effectively trading volume for share. Elevated commodity costs in H2 should support some pricing recovery, narrowing the volume-price gap.

Latam acceleration is the most actionable signal. Q1 Latam USG of +6.2% (Q4: +3.2%) represents a +300bps sequential improvement. Volume growth returned to +2.6% after three quarters of negative volume (Q4: -3.6%). The improvement is broad-based: Brazil sequential improvement in laundry and deodorants, plus Mexico growth. This is not a single-market story. If Latam volumes sustain at +2-3% for the rest of the year, the division-level USG could run above +5%, which would be a meaningful contributor to group guidance.

Beauty & Wellbeing weakness is expected but not structural. The division grew +3.6% USG, 49bps below division-level consensus, with Wellbeing specifically -LSD% on a tough +DD% comp from Liquid IV. Skin Care and Hair Care remain healthy (Skin +LSD%, Hair +HSD%), and the US personal care momentum (+MSD%) continues. The Wellbeing weakness is a function of comp math and product-specific optimization (increasing Liquid IV usage occasions, improving Nutrafol customer conversion), not category degradation. The division should reaccelerate in H2 as these initiatives take effect and comps ease.

Developed markets remain the drag. Europe USG was -0.9% (Q4: +0.1%), with volumes -1.2% and price +0.3%. North America slowed to +2.1% (Q4: +2.8%), though volumes remained positive (+2.2%). The European weakness is broad-based across categories, with only premium innovation-led growth in laundry, deodorants, and condiments offsetting declines elsewhere. This is a competitive market share issue, not a macro-driven slowdown—Unilever is losing ground in price-sensitive segments where private label penetration is rising. The FIFA-related campaigns and activations expected in Q2 may provide a temporary uplift, but the structural challenge in European grocery remains.

Key Divergences and Risks

Volume-price trade-off is unsustainable if pricing doesn't return. Q1 price was +0.9%, the lowest since 3Q23 and 90bps below consensus. Homecare price was -0.1%, meaning the division is effectively giving away pricing to gain volume. If commodity cost inflation forces a pricing catch-up in H2, volume momentum could decelerate sharply. The consensus FY26 price assumption of +1.9% may be too high if the competitive environment remains volume-focused, particularly in European discount channels.

Beauty & Wellbeing weakness could lengthen. Wellbeing reported -LSD% on a +DD% comp, but the magnitude of the slowdown was greater than expected. If Liquid IV usage occasion expansion and Nutrafol customer conversion fail to deliver visible reacceleration by Q3, the division could face an extended period of sub-3% growth, which would be a 300bps drag versus the pre-pandemic 6%+ trajectory.

FX remains a significant headwind. Reported sales growth was -3.3%, far below USG of +3.8%, due to a -7.7% FX drag. With FY26 guidance assuming -1.3% FX (Morgan Stanley estimate), further USD strength or EM currency weakness would compress reported EPS even if underlying operating profit holds. The accelerated share buyback (begun April 30) will mitigate some dilution but cannot offset a sustained FX shock.

Valuation or Trading Implications

Unilever trades at approximately 19x forward P/E, in line with its 3-year average but at a discount to the broader European staples sector. The 1Q26 beat provides near-term support, but the stock is unlikely to re-rate without evidence of sustained volume delivery in H2 and margin progression toward the 20%+ target. The key near-term catalyst is the Q2 Personal Care uplift from FIFA activations—if this materialises as guided (+MSD% acceleration), it would confirm that developed market weakness is tactical, not structural. The most actionable trade is to own the stock through the H2 commodity cost narrative: if elevated input costs force competitive pricing moves across the sector, Unilever’s Homecare volume base provides leverage that peers lacking scale in fabric cleaning do not have. Risk-reward is balanced but tilted to the upside if Latam and India momentum holds and Wellbeing recovers. The FY26 free cash flow yield of approximately 5% (including buyback) provides a floor, but the stock needs a volume growth narrative to sustain above 20x.

Appendix: Key Data Summary